1314951-25-1 Usage
Derivative of imidazole
The compound is derived from the imidazole structure, which is a heterocyclic aromatic organic compound with a five-membered ring containing four carbon and one nitrogen atom.
Carboxylic acid functional group
The presence of a carboxylic acid functional group (-COOH) in the compound contributes to its acidic properties and allows for the formation of salts, esters, and other derivatives.
Pharmaceutical intermediate
1-isobutyl-1H-imidazole-2-carboxylic acid is commonly used as an intermediate in the synthesis of pharmaceutical compounds, which means it is a reactant in the production of other, more complex molecules with potential therapeutic effects.
Potential applications in medicine and drug development
Due to its unique structure and properties, the compound has the potential to be used in the development of new drugs and therapies for various medical conditions.
Building block in organic synthesis
The compound may serve as a building block for the creation of new chemical entities with specific biological activities, allowing for the development of novel drugs with targeted effects.
Utilization in the pharmaceutical industry
Further research and development of 1-isobutyl-1H-imidazole-2-carboxylic acid could lead to its use in the production of novel drugs, contributing to advancements in the field of medicine and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 1314951-25-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,4,9,5 and 1 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1314951-25:
(9*1)+(8*3)+(7*1)+(6*4)+(5*9)+(4*5)+(3*1)+(2*2)+(1*5)=141
141 % 10 = 1
So 1314951-25-1 is a valid CAS Registry Number.
1314951-25-1Relevant articles and documents
Structure-guided optimization of 1H-imidazole-2-carboxylic acid derivatives affording potent VIM-Type metallo-β-lactamase inhibitors
Yan, Yu-Hang,Li, Wenfang,Chen, Wei,Li, Chao,Zhu, Kai-Rong,Deng, Ji,Dai, Qing-Qing,Yang, Ling-Ling,Wang, Zhenling,Li, Guo-Bo
, (2021/11/17)
Production of metallo-β-lactamases (MBLs) in bacterial pathogens is an important cause of resistance to the ‘last-resort’ carbapenem antibiotics. Development of effective MBL inhibitors to reverse carbapenem resistance in Gram-negative bacteria is still needed. We herein report X-ray structure-guided optimization of 1H-imidazole-2-carboxylic acid (ICA) derivatives by considering how to engage with the active-site flexible loops and improve penetration into Gram-negative bacteria. Structure-activity relationship studies revealed the importance of appropriate substituents at ICA 1-position to achieve potent inhibition to class B1 MBLs, particularly the Verona Integron-encoded MBLs (VIMs), mainly by involving ingenious interactions with the flexible active site loops as observed by crystallographic analyses. Of the tested ICA inhibitors, 55 displayed potent synergistic antibacterial activity with meropenem against engineered Escherichia coli strains and even intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL. The morphologic and internal structural changes of bacterial cells after treatment further demonstrated that 55 crossed the outer membrane and reversed the activity of meropenem. Moreover, 55 showed good pharmacokinetic and safety profile in vivo, which could be a potential candidate for combating VIM-mediated Gram-negative carbapenem resistance.
